Ningbo Menovo Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Ningbo Meinuohua Pharmaceutical Co., Ltd. was founded in 2004 and headquartered in Ningbo City, Zhejiang Province. It was listed on the main board of the Shanghai Stock Exchange on April 7, 2017, with stock abbreviation: Meinuohua and stock code 603538. The company is a comprehensive international pharmaceutical technology manufacturing enterprise specializing in the research and development, production, and sales of characteristic raw materials (including intermediates) and finished drugs. It is one of the enterprises exporting the most varieties of European characteristic raw materials in China and has been awarded the "Top 20 CDMO Enterprises in China" for many consecutive years. The company's products cover the treatment fields of cardiovascular, central nervous system, gastrointestinal tract, etc. Its core products include valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, and pregabalin, which have formed a commercial research and development, production, and sales system throughout the entire industry chain. With rigorous quality management and EHS management capabilities, solid process development, high standard large-scale production and manufacturing capabilities, and precise and efficient team combat capabilities, the company has established long-term, deep and stable cooperative relationships with well-known pharmaceutical enterprises both domestically and internationally. In the CDMO segmented industry and characteristic raw material medicine segmented industry, a high international brand awareness and competitive advantage have been formed. Since its listing, the company has leveraged the capital market and driven by a dual drive of "connotation based growth+extension based expansion". While consolidating and strengthening its characteristic raw material drug business, it has relied on continuous research and development innovation and business expansion to firmly deepen the integration strategy of "pharmaceutical intermediates, raw material drugs, and preparations", expand and extend upstream intermediate and downstream preparation businesses, in order to further improve the industrial chain layout and fully expand its integration advantages; At the same time, based on its competitive advantage in the field of specialty raw materials and customer network resources, the company continues to expand its CDMO business and accelerate the creation of a one-stop comprehensive CDMO service platform. By continuously improving the multi-dimensional strategic layout, with the CDMO business and pharmaceutical integration business as the core, actively carrying out the development and commercialization of cutting-edge medical products, and assisting the company in "secondary entrepreneurship", we are committed to building Minova into a domestic first-class, internationally renowned, and highly competitive international pharmaceutical technology manufacturing enterprise. |
| Headquarter | Ningbo |
| Establish Date | 2/19/2004 |
| Listed Code | 603538.SH |
| Listed Date | 4/7/2017 |
| Chairman | Yao Chengzhi. |
| CEO | Yao Chengzhi. |
| Website | www.menovopharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
